IgA Vasculitis Developing during Trastuzumab Emtansine Therapy for HER2-positive Breast Cancer
Abstract
An elderly woman undergoing trastuzumab emtansine (T-DM1) treatment for HER2-positive breast cancer visited our department with purpura, hematuria, proteinuria, and a decreased renal function. A skin biopsy revealed leukocytoclastic vasculitis with immunoglobulin A (IgA) deposition, confirming the diagnosis of IgA vasculitis. Owing to active renal lesions, the patient was treated with prednisolone and cyclophosphamide, which resulted in clinical remission. A renal biopsy performed five months post-treatment revealed persistent mild proliferative glomerulonephritis with fibrotic crescent formation. This case was considered to have T-DM1-associated IgA vasculitis. Although rare, an awareness of the possibility of serious adverse effects associated with drug administration is important.
Related
- Adjuvant Trastuzumab Deruxtecan Versus Trastuzumab Emtansine by Residual Cancer Burden in HER2-Positive Early Breast Cancer: A Decision Analysis
- 679 Novel 4-thiazolidinone derivative Les-4367 synergizes with trastuzumab and pertuzumab to suppress immune evasion markers in HER2-positive gastric cancer
- PTP1B supports survival and regulates CFL1 and HSP90a abundance in trastuzumab-resistant HER2-positive breast cancer.
- From Lethargy to Recovery: Central Diabetes Insipidus from Pituitary Metastasis in Recurrent HER2-Positive Breast Cancer Treated with Fam-Trastuzumab Deruxtecan-Nxki
- Progression-free survival of 23 months with second-line trastuzumab deruxtecan in HER2-positive gastroesophageal junction adenocarcinoma: a case report
BibTeX
@article{watanabe2026vasculitis,
title = {{IgA Vasculitis Developing during Trastuzumab Emtansine Therapy for HER2-positive Breast Cancer}},
author = {Nanami Watanabe and Shun Yoshida and Keiichi Osano and Kie Ohkoshi and Toshihisa Ishii and Makiko Konishi and Haruka Nakada and Naoki Ashizawa and Yuko Nakayama and Hiroshi Mitsui and Kazuya Takahashi and Ayumu Nakashima},
journal = {Internal Medicine},
year = {2026},
month = oct,
doi = {10.2169/internalmedicine.6751-25},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/65/19/65_6751-25/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - IgA Vasculitis Developing during Trastuzumab Emtansine Therapy for HER2-positive Breast Cancer
AU - Nanami Watanabe
AU - Shun Yoshida
AU - Keiichi Osano
AU - Kie Ohkoshi
AU - Toshihisa Ishii
AU - Makiko Konishi
AU - Haruka Nakada
AU - Naoki Ashizawa
AU - Yuko Nakayama
AU - Hiroshi Mitsui
AU - Kazuya Takahashi
AU - Ayumu Nakashima
PY - 2026
DA - 2026/10/01
JO - Internal Medicine
DO - 10.2169/internalmedicine.6751-25
UR - https://www.jstage.jst.go.jp/article/internalmedicine/65/19/65_6751-25/_article
AB - An elderly woman undergoing trastuzumab emtansine (T-DM1) treatment for HER2-positive breast cancer visited our department with purpura, hematuria, proteinuria, and a decreased renal function. A skin biopsy revealed leukocytoclastic vasculitis with immunoglobulin A (IgA) deposition, confirming the diagnosis of IgA vasculitis. Owing to active renal lesions, the patient was treated with prednisolone and cyclophosphamide, which resulted in clinical remission. A renal biopsy performed five months post-treatment revealed persistent mild proliferative glomerulonephritis with fibrotic crescent formation. This case was considered to have T-DM1-associated IgA vasculitis. Although rare, an awareness of the possibility of serious adverse effects associated with drug administration is important.
SN - 1349-7235
SN - 0918-2918
ER -